Premium
CELLULAR IMMUNITY TO HUMAN BASIC MYELIN PROTEIN IN WOMEN WITH DYSPLASIA AND CARCINOMA IN SITU OF THE CERVIX
Author(s) -
Singer Albert,
Shelton Jennifer,
Hill Shirley,
Potter Christopher
Publication year - 1975
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1975.tb00580.x
Subject(s) - carcinoma in situ , cervix , dysplasia , immunity , in situ , myelin basic protein , cervix carcinoma , carcinoma , medicine , biology , pathology , myelin , cancer research , immunology , cervical carcinoma , immune system , chemistry , cancer , cervical cancer , central nervous system , organic chemistry
Summary Sensitization to human myelin basic protein or encephalitogenic factor (EF), an antigen thought to be analogous to different human tumours, can be measured by the macrophage migration inhibition test (MMI). The MMI test was done on one occasion in 51 women with dysplasia and carcinoma in situ of the cervix; 20 women with non‐malignant gynaecological conditions served as controls Sensitization to EF was found in 71 per cent of women with carcinoma in situ and 42 per cent of women with dysplasia. None of the controls showed sensitization. Sensitization could not be related to histological evidence of cellular infiltration within the cervix.